Judith A Anesi1, Ebbing Lautenbach1, Irving Nachamkin2, Charles Garrigan2, Warren B Bilker3, Jacqueline Omorogbe3, Lois Dankwa3, Mary K Wheeler3, Pam Tolomeo3, Jennifer H Han1. 1. 1Division of Infectious Diseases,Department of Medicine,Perelman School of Medicine,University of Pennsylvania,Philadelphia,Pennsylvania. 2. 4Department of Pathology and Laboratory Medicine,Perelman School of Medicine,University of Pennsylvania,Philadelphia,Pennsylvania. 3. 2Center for Clinical Epidemiology and Biostatistics,Perelman School of Medicine,University of Pennsylvania,Philadelphia,Pennsylvania.
Abstract
OBJECTIVE: Resistance to extended-spectrum cephalosporins (ESC) among Enterobacteriaceae (EB) is increasingly prevalent. We sought to determine the clinical outcomes associated with community-onset ESC-resistant (ESC-R) EB urinary tract infections (UTIs) in a US health system. DESIGN: Retrospective cohort study.PatientsAll patients presenting to the emergency departments (EDs) or outpatient practices with EB UTIs between 2010 and 2013 were included. Exposed patients had ESC-R EB UTIs. Unexposed patients had ESC-susceptible EB UTIs and were matched to exposed subjects 1:1 on study year. Multivariable logistic regression analyses were performed to evaluate the association between ESC-R EB UTI and the outcomes of clinical failure and inappropriate initial antibiotic therapy (IIAT). RESULTS: A total of 302 patients with community-onset EB UTI were included, with 151 exposed and unexposed. On multivariable analyses, UTI due to an ESC-R EB was significantly associated with clinical failure (odds ratio [OR], 7.07; 95% confidence interval [CI], 3.16-15.82; P<.01). Other independent risk factors for clinical failure included infection with Citrobacter spp and need for hemodialysis. UTI due to an ESC-R EB was also significantly associated with IIAT (OR, 4.40; 95% CI, 2.64-7.33; P<.01). CONCLUSIONS: Community-onset UTI due to an ESC-R EB organism is significantly associated with clinical failure, which may be due in part to IIAT. Further studies are needed to determine which patients in the community are at high risk for drug-resistant infection to help inform prompt diagnosis and appropriate antibiotic prescribing for ESC-R EB.
OBJECTIVE: Resistance to extended-spectrum cephalosporins (ESC) among Enterobacteriaceae (EB) is increasingly prevalent. We sought to determine the clinical outcomes associated with community-onset ESC-resistant (ESC-R) EB urinary tract infections (UTIs) in a US health system. DESIGN: Retrospective cohort study.PatientsAll patients presenting to the emergency departments (EDs) or outpatient practices with EB UTIs between 2010 and 2013 were included. Exposed patients had ESC-R EB UTIs. Unexposed patients had ESC-susceptible EB UTIs and were matched to exposed subjects 1:1 on study year. Multivariable logistic regression analyses were performed to evaluate the association between ESC-R EB UTI and the outcomes of clinical failure and inappropriate initial antibiotic therapy (IIAT). RESULTS: A total of 302 patients with community-onset EB UTI were included, with 151 exposed and unexposed. On multivariable analyses, UTI due to an ESC-R EB was significantly associated with clinical failure (odds ratio [OR], 7.07; 95% confidence interval [CI], 3.16-15.82; P<.01). Other independent risk factors for clinical failure included infection with Citrobacter spp and need for hemodialysis. UTI due to an ESC-R EB was also significantly associated with IIAT (OR, 4.40; 95% CI, 2.64-7.33; P<.01). CONCLUSIONS: Community-onset UTI due to an ESC-R EB organism is significantly associated with clinical failure, which may be due in part to IIAT. Further studies are needed to determine which patients in the community are at high risk for drug-resistant infection to help inform prompt diagnosis and appropriate antibiotic prescribing for ESC-R EB.
Authors: Emily P Hyle; Adam D Lipworth; Theoklis E Zaoutis; Irving Nachamkin; Warren B Bilker; Ebbing Lautenbach Journal: Arch Intern Med Date: 2005-06-27
Authors: Jesús Rodríguez-Baño; Maria D Navarro; Luisa Romero; Miguel A Muniain; Marina de Cueto; María J Ríos; José R Hernández; Alvaro Pascual Journal: Clin Infect Dis Date: 2006-10-25 Impact factor: 9.079
Authors: E Esteve-Palau; G Solande; F Sánchez; L Sorlí; M Montero; R Güerri; J Villar; S Grau; J P Horcajada Journal: J Infect Date: 2015-09-14 Impact factor: 6.072
Authors: Haley J Appaneal; Theresa I Shireman; Vrishali V Lopes; Vincent Mor; David M Dosa; Kerry L LaPlante; Aisling R Caffrey Journal: BMC Geriatr Date: 2021-07-23 Impact factor: 3.921